Get the Stockscreener App
2.136
1.62%
-0.024
Nkarta Inc stock is traded at $2.136, with a volume of 204.10K.
It is down -1.62% in the last 24 hours and up +7.87% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.16
Open:
$2.2
24h Volume:
204.10K
Relative Volume:
0.29
Market Cap:
$151.28M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.89
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
-1.16%
1M Performance:
+7.87%
6M Performance:
+34.92%
1Y Performance:
-45.37%
1-Day Range:
$2.12
$2.22
1-Week Range:
$2.02
$2.3756
52-Week Range:
$1.31
$4.545
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.13 | 153.41M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.82 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.48 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.00 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.73 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How to use Fibonacci retracement on Nkarta Inc.2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
News impact scoring models applied to Nkarta Inc.July 2025 Weekly Recap & Real-Time Chart Pattern Alerts - newser.com
Can swing trading help recover from Nkarta Inc. losses2025 Sector Review & Safe Capital Preservation Plans - newser.com
Nkarta's (NKTX) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Evaluating Nkarta Inc. with trendline analysisJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - newser.com
Pattern recognition hints at Nkarta Inc. upsidePortfolio Growth Summary & Free Risk Controlled Daily Trade Plans - newser.com
Smart tools for monitoring Nkarta Inc.’s price actionPortfolio Growth Summary & Intraday High Probability Setup Alerts - newser.com
Why Nkarta Inc. stock could benefit from AI revolution2025 Major Catalysts & Verified High Yield Trade Plans - newser.com
Is Nkarta Inc. forming a bottoming base2025 EndofYear Setup & AI Enhanced Execution Alerts - newser.com
Has Nkarta Inc. found a price floorIPO Watch & Risk Controlled Swing Alerts - newser.com
Should you wait for a breakout in Nkarta Inc.2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - Defense World
What institutional flow reveals about Nkarta Inc.July 2025 Outlook & Fast Entry High Yield Tips - newser.com
Nkarta Inc Stock Analysis and ForecastPrice Support Zones & Exceptional Profit Trading - earlytimes.in
Is Nkarta Inc a good long term investmentAI-Driven Market Analysis & Compound Your Gains With Quality Stocks - earlytimes.in
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nkarta Inc Stock (NKTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shook David | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
8,638 |
19,004 |
190,955 |
| Levin Alyssa | See Remarks |
Jan 15 '25 |
Sale |
2.20 |
5,838 |
12,844 |
102,662 |
| Brandenberger Ralph | Chief Technical Officer |
Jan 15 '25 |
Sale |
2.20 |
7,447 |
16,383 |
124,796 |
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '25 |
Sale |
2.20 |
17,378 |
38,232 |
319,859 |
| Hager Alicia J. | Chief Legal Officer |
Jan 15 '25 |
Sale |
2.20 |
9,584 |
21,085 |
146,735 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):